Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.46 |
| ▸ | LTA4H | P09960 | 7/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.38 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8281118 | 0.80 | HRH3 (0.61) | CYP1A2CYP2D6HRH3HRH1CYP3A4 | |
| SCHEMBL12334539 | 0.73 | HRH3 (0.59) | CYP2D6HRH3 | |
| SCHEMBL4554100 | 0.71 | CHRNB2 (0.56) | HRH3L3MBTL1MBTD1L3MBTL3 | |
| SCHEMBL20038476 | 0.68 | SIGMAR1 (0.51) | CYP1A2CYP2D6HRH3LTA4HHRH1 | |
| SCHEMBL27420593 | 0.68 | MEN1 (0.40) | HRH1 | |
| SCHEMBL12049097 | 0.68 | CHRNB2 (0.51) | HRH3HRH1 | |
| SCHEMBL226521 | 0.67 | TDP1 (0.51) | CYP1A2HRH3CYP3A4L3MBTL1MBTD1 | |
| SCHEMBL20037986 | 0.65 | HRH3 (0.47) | HRH3LTA4HHRH1 | |
| SCHEMBL18291450 | 0.65 | ALDH1A1 (0.50) | HRH3L3MBTL1MBTD1L3MBTL3 | |
| SCHEMBL227159 | 0.64 | HRH3 (0.56) | CYP1A2CYP2D6HRH3CYP3A4L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10548911-B2 | Small molecule anti-scarring agents | UNIVERSITY OF ROCHESTER (US) | 2020-02-04 | — | — | US | disclosed |
| US-20170216332-A1 | SMALL MOLECULE ANTI-SCARRING AGENTS | UNIVERSITY OF ROCHESTER (US) | 2017-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170216332-A1 | SMALL MOLECULE ANTI-SCARRING AGENTS | COLGALT1, MMP1, FIBP | CYP1A2 4621/4885CYP2D6 4810/4885HRH3 2113/4885 |
| US-10548911-B2 | Small molecule anti-scarring agents | COLGALT1, MMP1, FIBP | CYP1A2 4621/4885CYP2D6 4810/4885HRH3 2113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.